23andMe Holding Co.Change company Symbol lookupSelect an option...ME 23andMe Holding Co.TNET TriNet Group IncBREA Brera Holdings PLCGVYB Golden Valley BankDHC Diversified Healthcare TrustMGNI Magnite IncINFN Infinera CorpPRSRW Prospector Capital Equity Warrants 1st Jan 2025 *W EXP 01/01/2025HYMCW Hycroft Mining Holding Equity Warrant Exp 29th May 2025 *W EXP 05/29/2025NVOS Novo Integrated Sciences IncGo
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 3.20x
- Price/Book (MRQ)
- 1.34x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in millions.
Company Officers
- Anne WojcickiCEO
- Paul JohnsonCOO
- Steve SchochCAO
- Kathy L. HibbsChief Admin.
- Kenneth J. HillanOther
Address
- 349 Oyster Point Boulevard
- South San Francisco, CA 94080
- Phone: (650) 938-6300
- Fax: (302) 531-3150
- https://investors.23andme.com/
Insider Trading
During the most recent quarter, 26K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.